Noble Life Sciences is delighted to welcome Dr. Catrina E. King as an Attending Veterinarian. Dr. King will be responsible for providing management and oversight of laboratory animal operations, professional veterinary, surgical services, and managing all phases of health care for the animal colony and technical guidance for staff and clients.
Dr. King has a solid background as a veterinarian as well as an academician. Dr. King earned her VMD and Ph.D. from the University of Pennsylvania and completed her post-doctoral training from Columbia University. Since 2012, Dr. King has served as a veterinarian in multiple clinics, hospitals, and Universities. From 2015-2017, Dr. King also served as a Senior Manager in Regeneron Pharmaceuticals’ Research Animal Facility. She has extensive experience providing veterinary care, consultation and oversight, training investigators in various biomethodologies and surgical techniques, and maintaining AAALAC-accreditation across multiple vivaria. In addition, from 2009-2012, Dr. King also served as an Adjunct Professor in Anatomy and Physiology, and Biology at Camden County College, NJ and Manhattan College, NY, respectively. She has also been involved in various veterinary and animal care organizations and associations.
Dr. King’s profound experience and knowledge in veterinary medicine will be an invaluable asset to Noble Life Sciences in ensuring preclinical scientific guidance and input on study designs, protocols, and feasibility for new inquiries for current and prospective clients.
“Noble Life Sciences’ is driven to offering best-in-class veterinary care, and we are excited to be adding Dr. King to our team. I believe the skills, passion, and energy that Dr. King brings to our animal care programs will go a long way to achieving our goals and deepens Noble life Sciences’ commitment to animal welfare. We look forward to Dr. King’s contributions which will reinforce Noble Life Sciences’ extensive offerings in preclinical research,” said Dr. Srujana Cherukuri, CEO at Noble Life Sciences.
About Noble Life Sciences
NLS is a preclinical contract research organization (CRO) owned and operated by scientists with decades of experience in drug, vaccine, and medical device development. The company provides integrated GLP and non-GLP preclinical services designed to accelerate the development of vaccines and therapeutics in the areas of cancer and infectious diseases. NLS offers services in pharmacology, disease models, early safety assessments, toxicology, PCR, Flow Cytometry, in vivo imaging, and cell-based assays.
For more information, please visit www.noblelifesci.com, or contact us at info@noblesci.com